WO1999033834A1 - Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments - Google Patents
Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments Download PDFInfo
- Publication number
- WO1999033834A1 WO1999033834A1 PCT/FR1998/002804 FR9802804W WO9933834A1 WO 1999033834 A1 WO1999033834 A1 WO 1999033834A1 FR 9802804 W FR9802804 W FR 9802804W WO 9933834 A1 WO9933834 A1 WO 9933834A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- radical
- compounds
- alkyl
- het
- Prior art date
Links
- 0 CC1(*)/C=*(\*)/C/C(/*C(*(C[C@@]2(*)[C@@](*)(CC3)C4=C5CCCCC4)C[C@]2(*)[C@]35N)=O)=C/C=C1 Chemical compound CC1(*)/C=*(\*)/C/C(/*C(*(C[C@@]2(*)[C@@](*)(CC3)C4=C5CCCCC4)C[C@]2(*)[C@]35N)=O)=C/C=C1 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
Definitions
- the present invention relates to new derivatives of general formula (I)
- the farnesyl transferase protein is an enzyme which catalyzes the transfer of the farnesyl group of farnesyl pyrophosphate (FPP) to the terminal cysteine residue of the tetrapeptide CAAX sequence of a certain number of proteins and in particular of the protein p21Ras, expressing the ras oncogene. .
- the ras oncogene (H-, N- or K-ras) is known to play a key role in cell signaling pathways and cell division processes.
- the mutation of the ras oncogene or its overexpression is often associated with human cancer: the mutated p21Ras protein is found in many human cancers and in particular in more than 50% of colon cancers and 90% of pancreatic cancers (Kohi et al ., Science, 260, 1834-1837, 1993).
- farnesyl transferase inhibitors are also active on tumor cell lines not expressing mutated or overexpressed ras, but having the mutation of an oncogene or the overexpression of an oncoprotein whose signaling pathway uses farnesylation of a protein, such as a normal ras (Nagasu et al, Cancer Research 55, 5310-5314, 1995; Sepp-Lorenzino et al., Cancer Research 55, 5302-5309, 1995).
- Farnesyl transferase inhibitors are inhibitors of cell proliferation and therefore anti-tumor and anti-leukemic agents.
- Patent FR 95/08296 describes farnesyl transferase inhibitors derived from benzoperhydroisoinsole, that is to say compounds for which the isoindole nucleus is condensed to a phenyl nucleus.
- the new compounds of general formula (I) have, among other modifications, a heterocyclic system Het condensed with an isoindole ring. It has now been discovered, and it is also the object of this invention, that the new products of general formula (I) of original structure, have, quite surprisingly and unexpectedly, a strong inhibitory activity on farnesyl transferase and prove to be remarkable anti-tumor and anti-leukemic agents.
- the biological activity of the compounds according to the invention is, inter alia, markedly improved, and this against all expectations, due to the replacement of the benzo cycle of the benzoperhydroisoindole skeleton by a heterocyclic system condensed with the isoindole skeleton.
- the present invention relates to new compounds of general formula I
- Het represents a condensed monocyclic or, bi-, or tri-cyclic system, for which each cycle, saturated or not, contains from 4 to 7 links, and for which at least one of the cycles contains from 1 to 4 heteroatoms, identical or different, independently selected from nitrogen, oxygen and sulfur atoms; this heterocyclic system, optionally substituted, can be condensed in the isoindole nucleus by any 2 of its adjacent atoms; Het preferentially represents a system 5- or 9-link aromatic mono- or bicyclic containing a nitrogen or sulfur atom; Het can also be chosen without limitation from the following radicals: thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzofuranyl, benzothienyl, chromenyl, indolyl, or quinolyl, as well as their iso isomers;
- - Ar represents - a phenyl radical optionally substituted by one or more atoms or radicals, identical or different, chosen from halogen atoms and alkyl radicals, such as methyl, the alkyl radicals possibly being perhalogenated, such as trifluoromethyl, alkenyls , mercapto, alkylthio, cyano or alkoxy, such as methoxy, the alkyl portion of which is optionally perhalogenated, such as trifluoromethoxy, or
- Ar represents or a phenyl radical optionally substituted, optionally substituted by an alkyl radical, preferably methyl, alkoxy, preferably methoxy, or trifluoromethyl, and this preferably in position 4, or alternatively a phenyl radical condensed with a heterocycle forming a bicyclic system such as 2,3-dihydro-1,4-benzodioxin-6-yl; advantageously, Ar represents a phenyl radical which is unsubstituted or substituted
- R4 represents an alkyl radical, such as methyl, or
- R 5 represents a hydrogen atom or an alkyl radical
- an alkyl radical such as methyl, optionally substituted by an amino, alkylamino, dialkoylamino, hydroxy, alkoxy, mercapto, alkylthio, alkoxycarbonyl, carboxy, cyano radical, a mono- or polycyclic aromatic radical and having 5 to 12 members, incorporating or not, one or more heteroatoms chosen from oxygen, nitrogen and optionally substituted sulfur atoms, said aromatic radical possibly being in particular the 2-, or 3-, or 4-pyridyl radical, preferably 3-pyridyl or 4-pyridyl, or the 2-, or 4-imidazolyl radical, or the 2- or 4-thiazolyl radical, or the pyridine N-oxide, or which may also be a phenyl radical optionally substituted by one or more atoms of halogen or by one or more trifluoromethyl groups, or by one or several alkyl or alkenyl, alkoxy, alkylthio, alkyllamino radicals,
- radicals - a hydroxy radical, - an amino radical optionally substituted, with one or two radicals, identical or different chosen from the radicals
- aryl such as phenyl, optionally substituted by one or more radicals, identical or different, chosen from alkyl, alkoxy radicals,
- arylcarbonyl such as benzoyl, optionally substituted by one or more radicals, identical or different, chosen from alkyl, alkoxy radicals,
- R represents a carboxy radical, or a -COOMe radical, or else a -CON ⁇ S MR ⁇ radical) for which when R5 represents a hydrogen atom, R ⁇ represents a alkyl radical, preferably methyl, substituted by an aryl radical, such as the phenyl or pyridyl radical, preferably 3-pyridyl, or 4-pyridyl or 2- or 4-imidazolyl or 2- or 4-thiazolyl; very advantageously, R represents a carboxy radical or a -COOMe radical or else a -CON (R 5 ) (R ⁇ ) radical for which when R 5 represents a hydrogen atom, Ro represents an alkyl radical, such as methyl substituted by an aryl radical such as the phenyl or pyridyl radical; even more preferably, R represents a carboxy radical or a -COOMe radical; - R
- one of the symbols Ri or R 2 represents a hydrogen atom and the other of the symbols represents an alkoxy radical such as methoxy, and more advantageously fixed in the ortho position of the phenyl ring.
- R 3 represents a hydrogen atom or an alkyl radical, an alkylthio radical
- R 3 represents a hydrogen atom or a methyl radical
- R 3 represents a hydrogen atom
- - X represents a methylene radical, or alken-l, l-diyl such as vinyldiyl or cycloalkan-l, l-diyl containing 3 to 6 carbon atoms,
- X represents a methylene or vinyldiyl group
- X represents the vinyldiyl group
- radicals or "alkyl” portions define the radicals or portions of hydrocarbons containing 1 to 6 carbon atoms, in straight or branched chain, and represent the radicals or portions methyl, ethyl, propyl, butyl, pentyl, hexyl and the isomers corresponding iso, dry, tert, preferably methyl, ethyl, propyl, butyl radicals and corresponding iso, dry, tert isomers
- alkenyl radicals or portions define the radicals or portions of unsaturated hydrocarbons containing 2 to 4 carbon atoms and represents the radicals or vinyl, aUyle, propene-2 yl, butene-1 or -2 or-3 yl portions, and the corresponding iso, dry, tert isomers
- the "alkoxy" radicals or portions define the radicals or portions containing 1 to 4 carbon atoms and represent the methoxy, ethoxy, propoxy, butoxy radicals and the corresponding iso, dry and tert isomers
- the compounds according to the invention have a general formula (I) for which:
- Het represents a thienyl or indolyl radical
- Ar represents or an optionally substituted phenyl radical, optionally substituted by an alkyl radical, such as methyl, alkoxy such as methoxy or trifluoromethyl; preferably in position 4, or a phenyl radical condensed with a heterocycle forming a bicyclic system such as 2,3-dihydro-1,4-benzodioxin-6-yl;
- R represents a carboxy radical, or a -COOMe radical, or also a -CON (R 5 ) (R6) radical for which R 5 represents a hydrogen atom, and Ré represents an alkyl radical such as methyl substituted by the phenyl radical or 3- or 4-pyridyl; one of the symbols Ri or R 2 represents a hydrogen atom and the other of the symbols represents an alkoxy radical such as methoxy, and more advantageously fixed in the ortho position of the phenyl ring, R 3 represents a hydrogen atom,
- X represents a vinyldiyl group
- the compounds according to the invention have a general formula (I) for which:
- Het represents a thienyl or indolyl radical
- Ar represents or a phenyl radical optionally substituted, optionally substituted by an alkyl radical such as methyl, alkoxy such as methoxy, the trifluoromethyl radical;
- R represents a carboxy radical, or a -COOMe radical; one of the symbols Ri or R 2 represents a hydrogen atom and the other of the symbols represents a methoxy radical, and more advantageously fixed in the ortho position of the phenyl ring,
- R 3 represents a hydrogen atom
- X represents a vinyldiyl group
- optical isomer or optically active form defines the pure form of said optical isomer or optionally the mixture of optical isomers "enriched", that is to say containing predominantly said optical isomer or said form.
- the compounds of general formula (I) in dextrorotatory form are preferred according to the invention.
- optical isomers mainly containing said optical isomer or the mixture of optical isomers mainly containing said optical isomer.
- R 2 are defined according to the general formula I and X defined as above, of its methyl ester or of a derivative of this acid such as a halide or anhydride, on a product of general formula (III):
- - Het, Ar, R, R 3 are defined according to the general formula I and - Gi represents a hydrogen atom, which can be obtained from a product of general formula (III) in which Lac Gi represents a protective group d an amino function such as a benzyl, benzyloxycarbonyl, tert-butoxycarbonyl radical or preferentially a benzyl radical subsequently transformed into a vinyloxycarbonyl radical when the heterocycle Het represents a sulfur heterocycle such as thiophene, by hydrogenolysis in the presence of a catalyst such as the paUadium on carbon, when Gi represents a benzyl or benzyloxycarbonyl radical, or by hydrolysis in acid medium, when Gi represents a tert-butoxycarbonyl, vinyloxycarbonyl or benzyloxycarbonyl radical.
- Lac Gi represents a protective group d an amino function such as a benzyl, benzyloxycarbonyl, tert-butoxycarbonyl radical or preferential
- Gi represents a benzyl radical
- definition for which Gi represents a benzyl radical is given only for illustrative purposes, and it is obvious to those skilled in the art to adapt the various protocols to the other groups protecting a function. amino such as a benzyl, benzyloxycarbonyl, tert-butoxycarbonyl or vinyloxycarbonyl radical.
- the reaction of the product of general formula (II) in acid form with the product of general formula (III) is carried out by operating in an organic solvent such as a halogenated uphatic hydrocarbon such as dichloromethane in the presence of an agent.
- condensation such as 1-ethyl-3- [3- (dimethylamino) propyl] carbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide or benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate and optionally an agent activation such as hydroxybenzotriazole at a temperature between 0 ° C and the reflux temperature of the reaction mixture.
- reaction of the product of general formula (II) in the form of a methyl ester with a product of general formula (III) is carried out by operating in an organic solvent such as dioxane or a halogenated uphatic hydrocarbon such as dichloromethane to a temperature between 0 ° C and the reflux temperature of the reaction mixture.
- organic solvent such as dioxane or a halogenated uphatic hydrocarbon such as dichloromethane
- reaction of the product of general formula (II) in the form of halide with the product of general formula (III) is carried out by operating in an organic solvent such as a halogenated ahathatic hydrocarbon such as dichloromethane in the presence of a base (tertiary aUphatic amine) at a temperature between 0 ° C. and the reflux temperature of the reaction mixture.
- organic solvent such as a halogenated ahathatic hydrocarbon such as dichloromethane
- a base tertiary aUphatic amine
- reaction of the product of general formula (II) in the form of an anhydride with the product of general formula (III) is carried out by operating in an organic solvent such as a halogenated uphatic hydrocarbon such as dichloromethane in the presence of a base.
- an organic solvent such as a halogenated uphatic hydrocarbon such as dichloromethane
- a base such as a halogenated uphatic hydrocarbon such as dichloromethane
- the saponification of a product of general formula (I) in which R represents an ester of general formula -CO-OR 4 into a product of general formula (I) in which R represents or contains a carboxy radical is carried out by means of a mineral base such as soda or potash or sodium carbonate in an organic solvent such as an alcohol such as methanol or ethanol or such as an ether such as dioxane, at a temperature between 20 ° C and reflux of the solvent.
- a mineral base such as soda or potash or sodium carbonate
- an organic solvent such as an alcohol such as methanol or ethanol or such as an ether such as dioxane
- -CO-Z with Z representing a radical -OR4 with R4 representing an alkyl radical can be obtained by esterification of a product of general formula (I) in which Z represents a hydroxy radical.
- esterification is carried out by means of an alcohol of general formula R4-OH in which R is defined as above by operating in acidic medium or by means of an alkyl halide of general formula R 4 -Hal in lacquer.
- Hal represents a halogen atom (iodine) operating in an alkaline medium (alkali or alkaline earth carbonate such as cesium carbonate) operating in an organic solvent such as dimethylformamide at a temperature between 0 and 50 ° vs.
- R represents a radical of general formula
- Z represents a radical -N (R 5 ) (R é ) in which R5 and R 6 are defined as in general claim (I) can be obtained by the action of a product of general formula:
- U is particularly advantageous to protect it by a protective group such as a tert-butoxycarbonyl, benzyloxycarbonyl or benzyl radical before the condensation of the amine of general formula HN (R 5 ) (R e ) on the appropriate acid and then to replace the protective group with a hydrogen atom, for example by hydrogenolysis using hydrogen in the presence of a catalyst such as paUadium on carbon, when U represents a benzyl or "benzyloxycarbonyl radical, or by hydrolysis in an acid medium, when it represents a tert-butoxycarbonyl or benzyloxycarbonyl radical.
- a protective group such as a tert-butoxycarbonyl, benzyloxycarbonyl or benzyl radical
- a protective group such as a tert-butoxycarbonyl, benzyloxycarbonyl or benzyl radical
- a protective group such as a tert-butoxycarbonyl, benzyloxycarbony
- U is particularly advantageous to protect it by a protective group such as an alkyl radical optionally substituted by a phenyl radical such as the benzyl radical before the condensation of the amine of general formula HN (R 5 ) (Re) on the appropriate acid and then of replacing the protective group with a hydrogen atom, for example by hydrogenolysis using hydrogen in the presence of a catalyst such as paUadium on carbon or by saponification under the conditions described above.
- a protective group such as an alkyl radical optionally substituted by a phenyl radical such as the benzyl radical before the condensation of the amine of general formula HN (R 5 ) (Re) on the appropriate acid and then of replacing the protective group with a hydrogen atom, for example by hydrogenolysis using hydrogen in the presence of a catalyst such as paUadium on carbon or by saponification under the conditions described above.
- R 5 represents a hydrogen atom or an alkyl radical containing 1 to 6 carbon atoms and R 6 represents an alkoxy radical substituted by a phenyl radical, the replacement of the alkoxy radical, substituted by a phenyl radical, by a hydroxy radical, carried out:
- the products of general formula (I) in which one of the symbols Ri or R 2 represents an alkylcarbonyloxy radical can be obtained by acylation of a product of general formula (I) in which one of the symbols R 1 or R 2 represents a hydroxy radical by means of an uphatic acid or a derivative of this acid such as a halide or the anhydride under the usual conditions of esterification.
- acylation of a product of general formula (I) in which one of the symbols R 1 or R 2 represents a hydroxy radical by means of an uphatic acid or a derivative of this acid such as a halide or the anhydride under the usual conditions of esterification.
- - Gi represents a hydrogen atom or a protective group of the amino group, such as benzyl, are of very particular interest according to the invention.
- - Het, Ar, R 3 are defined as above, - Gi represents a protective group such as the benzyl radical,
- R4 represents an alkyl radical containing 1 to 4 carbon atoms followed by the replacement of the group G x by a hydrogen atom
- heterocycle Het represents a thiophene nucleus
- an alkyl chloroformate such as vinyl chloroformate or ethyl chloroformate or 2-chloroethyl chloroformate or chloroformate of 2,2 , 2-trichloroethyl
- an organic solvent such as dichloromethane at a temperature between 0 ° C and ambient
- the acid hydrolysis of the intermediate carbamate generally using an aqueous solution 1 to 6 M hydrochloric acid, optionally in an organic solvent such as an alcohol, such as methanol or ethanol, or an ether such as tetrahydrofuran or dioxane.
- the Friedel-Crafts intramolecular cyclization of the product of general formula (IV) into the product of general formula (III) can be carried out by the action of an excess, of 3 to 15 molar equivalents, of a strong acid such that trifluoromethanesulfonic acid, optionally in the presence of trifluoromethanesulfonic anhydride in catalytic amount or optionally added in successive additions, operating in an organic solvent such as dichloromethane at a temperature between 0 ° C. and reflux from a few minutes to several days .
- a strong acid such that trifluoromethanesulfonic acid
- trifluoromethanesulfonic anhydride in catalytic amount or optionally added in successive additions
- the product of general formula (IV) can be obtained in a conventional manner by the action of an organomagnesium derivative of general formula Ar-Mg-Hal in which Lac Ar is defined as above and Hal represents a halogen atom, or d 'an organoUthian of general formula Ar-Li in which Ar is defined as above on a product of general formula (V):
- the ketone derivative of general formula (V) is treated with an excess of hydrazine hydrate, from 3 to 20 molar equivalents, at reflux in a solvent, such as ethanol, from a few minutes to a few hours.
- a solvent such as ethanol
- the hydrazone thus obtained is then stirred with an excess of iodine, in the presence of an auphatic tertiary amine such as triethylamine, at a temperature in the region of 20 ° C for a few hours to lead to an iodoethylene derivative.
- a bis (trifluoromethylsulfonyl) amide such as N, N- bis (trifluoromethylsulfonyl) aniline according to Mac Murry (Tetrahedron Lett., 1983 p979) or 2- [N, N-bis (trifluoromethylsulfonyl) amino] pyridine according to Comins ( Tetrahedron
- the coupling between the iodoethylene derivative, or the enol triflate, obtained previously and an arylboronic acid, conventionally obtained and optionally isolated in the form of trimeric anhydride is carried out by stirring in a two-phase system consisting of an organic solvent, preferably a mixture of toluene and methanol, and a basic aqueous solution, preferably a 2N solution of sodium carbonate, in the presence of a catalytic amount of derivative of ⁇ aUadium (O), preferably tetrakis (triphenylphosphine) paUadium, at a temperature close to reflux for a few hours to yield the arylethylene compound of general formula (VI).
- a two-phase system consisting of an organic solvent, preferably a mixture of toluene and methanol, and a basic aqueous solution, preferably a 2N solution of sodium carbonate
- the coupling between the iodoethylene derivative, or the enol triflate, previously obtained with an arylstannane, conventionally obtained is carried out by stirring in a polar aprotic organic solvent, preferably dimethylformamide or N-methylpyrroUdone, in the presence of a catalytic amount of paadium (O) derivative, preferably tetrakis
- This second process is particularly advantageous when the aryl radical Ar represents a possibly substituted phenyl nucleus, in para or meta-para or meta-para-meta 'positions by electron donor groups, or a heterocyclic radical naturally rich in electrons or a heterocycUc radical suitably substituted by electron donating groups, this second method consists in reacting directly, according to tandem intermolecular and then intramolecular reactions of the Friedel-Crafts type, an aromatic or heterocycUc Ar-H hydrocarbon with a compound of formula general (V) in an organic solvent in the presence of an excess of strong acid such as trifluoromethanesulfonic acid, or éventueUement of a Lewis acid such as aluminum chloride.
- a Lewis acid such as aluminum chloride
- the developed procedure consists in condensing the product of general formula (V) (I) with an excess of trifluoromethanesulfonic acid (from 5 to 20 molar equivalents) in an organic solvent such as dichloromethane at a temperature close to from a few hours to several days.
- an organic solvent such as dichloromethane
- this reaction leads either directly to the compounds of general formula (III) or intermediate to the compounds of general formula (VI) which are then cyclized as described above into compounds of general formula (III).
- the compounds of general formula (I) or (III) can be obtained by functionalization of the substituents of the aromatic ring Ar of the compounds of general formula (I) or (III) corresponding, by appUcation or adaptation of the known methods of usual functionalizations , such that, and not limited to: functional substitution reactions (for example the replacement of a halogen atom by a cyano group by coupling with paUadium), dealkylation reactions (for example by BBr 3 ), alkylation reactions (in particular alkylation-cyclization reactions by action of BBr 2 ).
- functional substitution reactions for example the replacement of a halogen atom by a cyano group by coupling with paUadium
- dealkylation reactions for example by BBr 3
- alkylation reactions in particular alkylation-cyclization reactions by action of BBr 2 ).
- Gi represents a benzyl radical can be obtained by the action of an N-trialcoylsUylmethyl-N-alkoxymethyl-amine bearing an amino protecting group such as a benzyl radical, such as N-trimethylsUylmethyl-Nn.butoxymethyl-benzylamine which can be prepared under the conditions described in Chem. Pharm. BuU., 276 (1985), on a cyclohexenone derivative of general formula:
- the reaction is carried out in an organic solvent such as a halogenated uphatic hydrocarbon such as dichloromethane in the presence of a strong acid such as trifluoroacetic acid at a temperature between 0 ° C. and the reflux of the reaction mixture.
- organic solvent such as a halogenated uphatic hydrocarbon such as dichloromethane
- a strong acid such as trifluoroacetic acid
- laqueUe R 3 and Het are as defined in general formula (I), by means of an aUphatic alcohol of general formula R_ ⁇ OH containing 1 to 4 carbon atoms in the presence of a mineral acid such as hydrochloric acid or l sulfuric acid at a temperature between 0 ° C and the reflux temperature of the reaction mixture, or by means of an alkyl halide (iodide), in the presence of an organic base, such as 1,8-diazabicyclo [5.4.0] undec-7-ene, or mineral, such as cesium carbonate, operating in a solvent chosen from tetrahydrofuran, dimethylformamide, acetone or dioxane.
- a mineral acid such as hydrochloric acid or l sulfuric acid at a temperature between 0 ° C and the reflux temperature of the reaction mixture
- an alkyl halide iodide
- an organic base such as 1,8-diazabicyclo [5.4.0] undec-7-ene
- mineral such as
- Cyclohex-1-ene-1-carboxylic acids of general formula (VIII) in which Het and R 3 are defined as above, can be obtained from cyclohexane-1-ol-1-carboxylic acids of general formula ( IX)
- Het and R are defined as above, or optionally corresponding esters, on methyl vinyl ketone, generally operating in a hydro-alcoholic medium such as a methanol-water mixture in the presence of a mineral base such as soda (according to J. Org. Chem., 1971, 3707).
- a hydro-alcoholic medium such as a methanol-water mixture
- a mineral base such as soda
- heteroarylpyruvic acids of general formula (X) in which R represents a hydrogen atom can be obtained either by hydrolysis of the corresponding ⁇ -acetamidovinylic acids of general formula (XI)
- the hydantoines of general formula (XII) can be obtained by heating the corresponding aldehydes of general formula (XIII), according to Org. Synth. Neck. Vol V p.267, with hydantoin in the presence of an organic base such as piperidine at a temperature close to 130 ° C.
- esters of heteroarylpyruvic acids of general formula (X) in which R represents an alkyl or alkylthio radical can be obtained by the action of the corresponding carboxylic acids of general formula (XTV)
- R 3 represents an alkyl or alkylthio radical on the alkyl oxalate, such as ethyl oxalate, in the presence of an organic base such as n-butyUithium, at a temperature close to -70 ° C., followed by decarboxylation, operating under the conditions described in Tetrahedron Lett., 1981, 2439-42.
- Z represents a radical -OR_t or -N (R5) (R e ) can be obtained from a product of general formula (IV) in which la R represents a carboxy radical by esterification and amidation under the conditions described above, followed by cyclization by action of trifluoromethanesulfonic acid under the conditions described above.
- Ri, R 2 , R 3 , X are defined as above and R represents a COOR 4 radical in which R t is defined as above can also be obtained at starting from a product of general formula (V) in which Het, R 3, ⁇ are defined as above and Gi represents a hydrogen atom.
- the products of general formula (XV) can be obtained by the action of an acid of general formula (II), or of its chloride, or of its anhydride on a product of general formula (V) in which lac Gi represents an atom of hydrogen operating under the conditions described above for the action of a product of general formula (II) on a product of general formula (III) in which Gi represents a hydrogen atom,
- R4 and X are defined as above, by the action of a metallic derivative of general formula Ar-Mg-X or Ar-Li in lacquer X represents a halogen atom on a product of general formula (XV) by operating under the conditions described above for the action of an organo-magnesian or organo-Uthian derivative of general formula Ar-Mg-X or Ar-Li on a product of general formula ( V).
- the product of general formula (XVI) is transformed into product of general formula (I) in which Het, Ar, Ri, R 2 , R 3 , R 4 and X are defined as above, by the action of trifluoromethanesulfonic acid, or of a Lewis acid, on the product of general formula (XVT) by operating under the conditions described above for the action of trifluoromethanesulfonic acid, or d : a Lewis acid, on a product of general formula (IV).
- reaction mixtures obtained by the various methods described above are treated according to conventional physical (evaporation, extraction, distillation, chromatography, crystallization, for example) or chemical (formation of salts, for example) methods.
- the compounds of formula (I) can optionally be converted into addition salts with a mineral or organic acid by the action of such an acid in an organic solvent such as an alcohol, a ketone, an ether or a solvent chlorine. These salts are also part of the invention.
- optical isomers of the products of general formula (I) can be obtained according to the usual methods of separation from the corresponding racemic product. It is particularly advantageous to carry out the separation by high performance liquid phase chromatography using a chiral stationary phase of Pirkle type modified by eluting with a suitable solvent.
- a phase can preferably be used whose chiral selector, which is preferably 3,5-dinitro-phenylalanine, is separated from the site by an aminoalkyl arm containing 3 to 14 carbon atoms attached to the amino functions of an aminopropyl site and whose uranium functions are blocked by trialkylsilyl radicals.
- This chiral phase can be defined by the following structure:
- R ' identical or different, and R ", identical or different, represent alkyl radicals containing 1 to 10 carbon atoms
- G represents an electron-attracting group
- n represents an integer between 3 and 13 inclusive , whose porosity is close to 100 A
- the chiral phase can be prepared by action on an aminopropyl base of the anhydride of an aminoalkanoic acid containing 4 to 14 carbon atoms whose amino function is protected by a protective group such as the tert-butoxycarbonyl radical, followed by blocking of 'a part of the sUanol functions with Si (R') radicals as defined above, then, after elimination of the groups protecting the amino function, of the amidification by means of an amino acid of general formula:
- the action of the anhydride of a protected aminoalkanoic acid on the aminopropyl site is carried out by operating in an anhydrous organic solvent such as dimethylformamide at a temperature in the region of 20 ° C.
- the blocking of the sUanol functions by -Si (R ′) groups as defined above is carried out by the action of a halotrialkylsUane on the surface aminopropyl grafted with aminoalkanoyl residues by operating in an organic solvent such as methylene chloride in the presence of a basic agent such as pyridine.
- the removal of the protective groups from the aminoalkanoyl residues is generally carried out, when the protective group is a tert-butoxycarbonyl radical, by the action of trifluoroacetic acid in an organic solvent such as methylene chloride.
- Amidification by means of phenylalanine, the amino function of which is protected, is carried out in the presence of a condensing agent such as N-ethoxycarbonyl-2-ethoxy-1,2-dihydro-quinoline, operating in an anhydrous organic solvent such as dimethylformamide.
- a condensing agent such as N-ethoxycarbonyl-2-ethoxy-1,2-dihydro-quinoline, operating in an anhydrous organic solvent such as dimethylformamide.
- the blocking of the residual solan functions by -Si (R ") 3 radicals as defined above is generally carried out by means of trialkylsUyl-imidazole by operating in an organic solvent such as methylene chloride.
- the aminopropyl site can be prepared by the action of aminopropyl-triethoxysane on a surface whose porosity is close to 100 A by operating in the presence of imidazole in an anhydrous organic solvent such as an aromatic hydrocarbon such as toluene.
- the present invention also relates to any pharmaceutical composition containing at least one product of general formula in combination with one or more pharmaceutically acceptable dUuants or adjuvants, whether inert or biologically active.
- the new products of general formula (I) can be in the form of non-toxic and pharmaceutically acceptable salts.
- These non-toxic salts include the salts with mineral acids (hydrochloric, sulfuric, hydrobromic, phosphoric, nitric) or organic (acetic, propionic, succinic, maleic, hydroxymaleic, benzoic, fumaric, methanesulphonic, trifluoroacetic or oxic acids) mineral (soda, potash, uthine, lime) or organic (tertiary amines such as triethylamine, piperidine, benzylamine) depending on the nature of the compounds of general formula (I).
- the present invention also relates to the use of the compounds of general formula (I) according to the invention for the preparation of pharmaceutical compositions useful for inhibiting farnesyl transferase, and more particularly for inhibiting farnesylation of the ras oncogene.
- the present invention relates to the use of the compounds of general formula (I) according to the invention for the preparation of pharmaceutical compositions useful for the treatment of diseases caused by cell proliferation by inhibition of farnesyl transferase and in particular for the treatment from diseases of the European Union to cell proliferation, overexpressing any of the H-Ras, N-Ras or K-Ras oncoproteins, or having a mutation in any of the corresponding ras oncogenes.
- the invention relates in particular to the use of the compounds of general formula (I) according to the invention for the preparation of pharmaceutical compositions useful for the treatment of diseases caused by cellular, benign or benign proliferation, cells of various tissues and / or organs, including muscle, bone or connective tissue, skin, brain, lungs, sex organs, lymphatic or renal systems, breast or blood cells, liver, digestive system, colon, pancreas and the thyroid or adrenal glands, and including the following pathologies: psoriasis, restenosis, solid tumors, Kaposi's sarcoma, carcinomas, cholangiocarcinoma, choriocarcinoma, neuroblastoma, Wilms tumor, Hodgkin's disease, melanomas, teratocarcinomas, gUomes, multiple myelomas, chronic lymphocytic leukemias, acute or chronic granulocytic lymphomas, and cancers such as pancreatic, colon, lung, ovarian, breast, brain, prostate
- the invention particularly relates to the use of the compounds of general formula (I) according to the invention for the preparation of pharmaceutical compositions useful for the treatment of cancers such as cancers of the pancreas, colon, lung, ovary , breast, brain, prostate, liver, stomach, bladder or testicles, and more advantageously cancer of the colon and pancreas, in particular of the colon.
- cancers such as cancers of the pancreas, colon, lung, ovary , breast, brain, prostate, liver, stomach, bladder or testicles, and more advantageously cancer of the colon and pancreas, in particular of the colon.
- the compounds according to the invention can also be used for the preparation of medicaments for the treatment and / or prevention of pathological conditions due to cell signaling pathways associated with farnesyl transferase, or to their consequences or symptoms.
- the compounds according to the present invention can be used for the preparation of medicaments for the treatment and / or prevention of diseases associated with the signaling pathways Ueus to Ras.
- the compounds according to the invention can be used for the preparation of medicaments in the treatment and / or prevention of transplant rejection (such as a transplant) (O'Donnel et al, 1995, Kidney International, vol.48, suppl. 52, pS29-33).
- the compounds according to the invention can be useful for the preparation of medicaments for inhibiting angiogenesis and acting on tumor growth (J. Rak et al., Cancer research, 55, 4575-4580, 1995), these anti properties -angiogenesis can be also useful for the treatment of certain forms of blindness to retinal vascularization;
- the compounds according to the invention can also be used for the preparation of medicaments for the treatment and / or prevention of Ueus diseases with (pro- or anti) apoptotic dysfunction comprising in particular the cancers mentioned above;
- -hepatitis delta and associated viruses JSGlenn et al., Science, 256, 1331-1333, 1992), as well as, without limitation, the Herpes, Pox, Epstein-Barr, Sindbis, and adeno; -inflammatory and / or autoimmune diseases, such as, by way of illustration, polyarthritis, polyarticular rheumatism, intestinal inflammation, pulmonary edema, myocardial infarction, fibrosis, lupus erythematosus, such as Kaposi's disease , immuno-glomerulonephritis, autoimmune diabetes; -vascular diseases (arteriosclerosis or other arterial lesions), restenosis after angioplasty or vascular surgery;
- bone diseases regulation of bone metabolism, for example Paget's disease, hypercalcemia, bone metastases, osteoporosis; -diseases associated with a high cholesterol level, such as high cholesterol, high hyperemia, hyperproproteinemia, nephrotic hyperUpemia, or atherosclerosis (Massy et al, Lancet, 347, 102-103, 1996);
- -neurodegenerative disorders such as Parkinson's disease, Alzheimer's, amyotrophic lateral sclerosis, neurological disorders associated with viral diseases such as AIDS, withdrawals, atrophies or spino-cerebral degenerations; and for the prevention and / or treatment of the following diseases: AIDS in particular, or also, polycystic kidney (DLSchaffner et al., American Journal of Pathology, 142, 1051-1060, 1993), neurofibromatosis, pulmonary fibrosis , arthritis, psoriasis, glomerulonephritis, hypertrophic scar formation, endotoxic shock; as well as myodysplastic syndromes, aplastic anemia, ischemic lesions associated with infarctions, lesions associated with strokes and, arrhythmias, atherosclerosis, liver diseases caused by toxins or alcohol, hematological diseases, including in particular chronic or aplastic anemia, degenerative diseases of the muscle-skeleton system, including in particular osteoporosis and arthritis,
- Said treatment can be carried out in particular by inhibiting tumor growth, in particular by inhibiting farnesyl transferase, or by inhibiting the growth of tumors expressing the activated ras oncogene.
- Another object of the present invention is any combination of a product of general formula (I) with one or more compatible and pharmacologically active compounds and / or radiotherapy treatment; in particular for administration simultaneously, separately or spread over time; said compounds preferably being active ingredients known for their activity inhibiting cell proliferation and particularly for their activity in the treatment of cancer; They may preferably be antiproliferative compounds which act at any one of the stages of the signaling pathway of the ras oncogene such as a tyrosine kinase inhibitor, or another farnesyl transferase inhibitor, or an HMG-Co-reductase inhibitor, or the cytotoxic compounds commonly used in the treatment of cancer;
- the other treatments and / or therapeutic products which can be used in combination with the products of general formula (I) can be chosen from antineoplastic drugs, monoclonal antibodies, munological therapies or radiotherapy or modifiers of biological responses.
- Response modifiers include, but are not limited to, lymphokines and cytokines such as interleukins, interferons (a, ⁇ or ⁇ ) and TNF.
- chemotherapeutic agents used in the treatment of disorders due to abnormal proliferation of cells include, but are not limited to, alkylating agents such as nitrogen mustards such as mechloretamine, cyclophosphamide, melphalan and chlorambucU, alkyl sulfonates such as busulfan, nitrosoureas such as carmustine, lomustine, semustin and streptozocin, triazenes such as dacarbazine, antimetabugs like analogs of foUc acid such as methotrexate, pyrimidine analogs such as fluorouracU and cytarabine, purine analogs like mercaptopurine and thioguanine, natural products like vinca alkaloids like vinblastine, vincristine and vendesine, derivatives of taxoids, topoisomerase inhibitors such as derivatives of camptothecin, epipodophyUotoxins like etoposide and teniposide, antibiotics like
- the products according to the invention can be used to prevent or delay the onset or recurrence of pathological conditions or to treat these pathological conditions.
- the products according to the invention can be administered by oral, parenteral or or intraperitoneal or rectal route, preferably by oral route.
- the compositions for oral administration include tablets, pUules, powders or granules.
- the active product according to the invention is mixed with one or more inert diluents such as sucrose, lactose or starch.
- These compositions can include substances other than diluents, for example a lubricant such as magnesium stearate.
- compositions for oral administration may be used pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs containing inert diluents such as water or paraffin hula.
- diluents such as water or paraffin hula.
- These compositions can also include substances other than diluents, for example wetting, sweetening or flavoring products.
- compositions according to the invention for parenteral administration can be aqueous or nonaqueous sterile solutions, suspensions or emulsions.
- solvent or vehicle propylene glycol, a polyethylene glycol, vegetable oils, in particular oil or injectable organic esters can be used, for example ethyl oleate.
- These compositions can also contain adjuvants, in particular wetting agents, emulsifiers and dispersants.
- Sterilization can be done in several ways, for example using a bacteriological filter, incorporating sterilizing agents into the composition or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
- compositions for rectal administration are suppositories which may contain, in addition to the active product, excipients such as cocoa butter.
- excipients such as cocoa butter.
- the doses used to implement the methods according to the invention are those which allow a prophylactic treatment or a maximum therapeutic response.
- the doses vary according to the form of administration, the particular product selected and the specific characteristics of the subject to be treated. In general, the doses are those which are therapeutically effective for the treatment of disorders due to abnormal cell proliferation, and in particular cytostatic treatment. Products according to the invention can be administered as often and as long as necessary to achieve the desired therapeutic effect.
- the doses are between 0.1 and 10,000 mg / kg per day in humans, preferably between 100 and 2,000 mg / kg per day, preferably orally. It is understood that, in order to choose the most appropriate dosage, the route of administration, the patient's weight, his general state of health, his age and all the factors which may influence the effectiveness of the treatment must be taken into account. .
- the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
- Example C illustrates the compositions according to the invention.
- Stage D 21.84 g (9.1 mmol) 6- (3-thienyl) -3-oxo-cyclohexan-1-ol-1-carboxylic acid are heated at reflux for three hours in 220 cm 3 of toluene presence of 2.2 g of para-toluene sulfonic acid.
- the reaction mixture is then cooled to 5 ° and the precipitate formed is filtered, washed with isopropyl ether and then dried at 50 ° C.
- Step EA a solution of 18.45 g (8.3 mmol) of 6- (3-thienyl) -3-oxo-cyclohexene-1-carboxylic acid (RS), in 250 cm 3 of dry acetone, successively add 7.5 cm ⁇ (12 mmol) of methyl iodide and 16.8 cm ⁇ (11.2 mol) of 1,8-diazabicyclo [5.4.0] undec-7-ene drop by drop, then brings to reflux for two hours and thirty minutes. After hot filtration of an insoluble material and concentration of the solvents under reduced pressure, the residue is purified by flash chromatography on silica gel (230-400 mesh), eluting with dichloromethane. 14.84 g (76%) of methyl 6- (2-thienyl) -3-oxo-cyclohexene-1-carboxylate- (RS) are thus obtained in the form of a yellow powder, the characteristics of which are as follows:
- hydrolysis is carried out by adding 50 cm4 of a saturated aqueous ammonium chloride solution.
- the organic phase is decanted, washed successively with 10 cn-H of a saturated aqueous solution of ammonium chloride then with twice 10 cm ⁇ of water, dried over sodium sulfate and concentrated under reduced pressure.
- Stage I 645 mg (1.5 mmol) of 2-benzyl-4 ) 8-ethano-8-phenyl-2,3,3a, 4,8,8a-hexahydro-1H are stirred for twenty hours at room temperature -thieno [2,3-f] isoindole-3a- methyl carboxylate- (3aRS, 4SR, 8SR, 8aRS) and 0.2 cm 3 (3 mmol) of vinyl chloroformate in 10 cm 3 of dichloromethane. After evaporation of the dichloromethane, the residue is stirred for two hours at reflux in 7 cm 3 of methanol and 3 cm 3 of a 5N solution of hydrochloric gas in isopropanol.
- aqueous phase is washed with three times 10 cm 3 of diethyl ether and then acidified with a normal aqueous solution of hydrochloric acid to a pH close to 2 in the presence of 20 cm 3 of ethyl acetate.
- the organic phase is washed with water, dried over sodium sulfate and concentrated under reduced pressure. The residue is purified by recrystallization from 10 cm 3 of 50% aqueous ethanol. 160 mg (50%) of 4,8-ethano-2- [2- (2-methoxyphenyl) propenoyl] -8-phenyl-2,3,3a, 4,8,8a-hexahydro-1H acid are thus obtained.
- -thieno [2,3- f] isoindole-3a-carboxyUque- (3aRS, 4SR, 8SR, 8aRS), in the form of a white solid with the following characteristics:
- Step F By operating as in step J of Example 1, but starting from 1.3 g (3.7 mmol) of 4,8-ethano-8- (4-methylphenyl) -2,3,3a ) 4 ) 8.8a-hexahydro-1H-thieno [2,3-f] isoindole- methyl 3a-carboxylate- (3aRS, 4SR, 8SR, 8aRS), 710 mg (4 mmol) acid 2- ( 2-methoxyphenyl) propenoic acid, 770 mg (4 mmol) of 1-ethyl-3- [(3-dimethylamino) ⁇ ropyl] carbodiimide hydrochloride and 50 mg (0.4 mmol) of N-hydroxybenzotriazole hydrate in 30 cm 3 of dichloromethane, for twenty hours at room temperature, after purification by flash chromatography on silica gel (230-400 mesh), the elution is obtained with a cyclohexane-ethyl acetate mixture (
- the soda obtained is separated by fUtration and washed successively with 2 times 2500 cm 3 of dichloromethane, twice 2500 cm 3 of methanol, 2 times 2500 cm 3 of tetrahydrofuran, twice 2500 cm 3 of dichloromethane and 2 times 2500 cm 3 of diethyl ether and then dried under reduced pressure at a temperature in the region of 20 ° C.
- the floor is separated by filtration and washed successively with 2 times 2500 cm 3 of dichloromethane, 2 times 2500 cm 3 of a dichloromethane-diisopropyl-ethylamine mixture (70-30 by volume), 2500 cm 3 of dichloromethane, 2 times 2500 cm 3 of tetrahydrofuran, 2 times 2000 cm 3 of methanol and 2 times 2000 cm 3 of diethyl oxide and then dried under reduced pressure at a temperature in the region of 50 ° C.
- the sUice is separated by filtration on sintered glass and is then washed with 2 times 2500 cm 3 of dichloromethane, 2 times 2500 cm 3 of tetrahydrofuran, 2500 cm 3 of N, N-dimethylformamide and 2500 cm 3 of dichloromethane.
- the surface thus washed is resuspended in 2500 cm 3 of N, N-dimethylformamide.
- 108 g of N-benzoyl-3,5-dinitro-D-phenylalanine and 75 g of N-ethoxycarbonyl-2-ethoxy-1,2-dihydro-quinoline are successively added, followed by stirring overnight at 20 ° C.
- the syringe is separated by filtration on sintered glass and is washed successively with 2 times 2500 cm 3 of dichloromethane, 2 times 2500 cm 3 of tetrahydrofuran, 2 times 2500 cm 3 of methanol and 2 times 2500 cm 3 of diethyl ether.
- the anhydride of N-tert-butoxycarbonyl-11-amino-decanoic acid can be prepared in the following manner:
- N-tert-.butoxycarbonyl-11-amino-undecanoic acid can be prepared according to J. Org. Chem., 41, 1350 (1976).
- Stage D To a solution of 400 mg (1.5 mmol) of 2- (2- methoxyphenyDpropenoic acid in 15 cm 3 of dichloromethane containing 3 drops of N, N-dimethylformamide, 0.2 cm 3 (1.75 mmol) is added of oxalyl chloride and the mixture is brought to 40 ° C.
- Step E (SON 2807) A solution of 40 g (0.0995 mol) of methyl 2-benzyl-4- (3-indolyl) -7-oxo-octahydroisoindole-3a-carboxylate- (3aRS, 4SR, 7aRS), and 85 g (1 , 7 mol) of hydrazine hydrate in 400 cm3 of methanol is brought to reflux for two hours. After concentrating methanol under reduced pressure, the residue is taken up in 400 cm3 of dichloromethane, washed with three times 150 cm3 of distilled water, dried over magnesium sulphate and concentrated under reduced pressure.
- reaction mixture After dilution with 100 cm3 of distilled water, the reaction mixture is extracted with 150 cm3 of ethyl acetate, washed with three times 150 cm3 of a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and then concentrated under reduced pressure. After purification by flash chromatography on sugar gel (230-400 mesh), 17.7 g (71%) of eluent are obtained with a mixture of cyclohexane and ethyl acetate (80-20 by volume).
- reaction mixture is further stirred for four hours at a temperature in the region of 20 ° C. and poured into 30 cm 3 of distilled water.
- the organic phase is separated by decantation, washed twice with 30 cm 3 of distilled water and then three times 10 cm 3 with a normal aqueous solution of hydrochloric acid, dried over magnesium sulfate and concentrated under reduced pressure.
- the aqueous phase is washed once with 20 cm 3 of dichloromethane and then acidified with a normal aqueous solution of hydrochloric acid to a pH close to 1. Extraction is carried out with 2 times 20 cm 3 of dichloromethane.
- the organic phase is separated by decantation, washed with distilled water, dried over magnesium sulfate and concentrated under reduced pressure.
- the soda obtained is purified by recrystallization from methanol. 90 mg (15%) of 4.10-ethano-2- [2- (2-methoxyphenyl) -2-propen-1-oyl] -10- (4-methylphenyl) -2.3 are thus obtained.
- thieno [2,3-f] isoindole-3a-carboxamide- (3aRS, 4SR, 8SR, 8aRS) can be obtained as follows:
- Step AA a solution cooled to 0 S C of 1.35 g (2.8 mmol) of methyl 2-benzyl-7-oxo-4- (3-thienyl) -octahydroisoindole-3a-carboxylate- (3aRS, 4SR, 7aRS) and 1.36 g
- Step B By operating as in step I of Example 1, but starting from 584 mg (1.2 mmol) of 8- (benzo-1,4-dioxan-6-yl) -2-benzyl-4 , 8-ethano-2,3,3a, 4,8,8a-hexahydro-1H-
- Stage D By operating as in example l ', but starting from 430 mg (0.77 mmol) of 8- (benzo- l, 4-dioxan-6-yl) -4,8-ethano-2- [2- (2-methoxyphenyl) propenoyl] -2 ) 3.3a, 4,8,8a-
- the farnesyl transferase activity is measured by the farnesylated amount of K-ras substrate or of substrate derived from the peptide corresponding to its C-terminal part, the f arnesyl group being provided by farnesyl pyrophosphate (FPP).
- FPP farnesyl pyrophosphate
- the biotinylated substrate used representative of K-ras: BIOT- ( ⁇ A) - SKDG- (K) 6 -SKTKCVIM, is [H] farnesyl on its cysteine C, by farnesyl transferase in the presence of [H] FPP. It is then brought into contact with balls PVT * -streptavidin (AMERSHAM) ®, and is quantified by proximity scintUlation (SPA assay) between tritium and PVT biUes, thanks to the streptavidin / biotin interaction.
- BIOT- ( ⁇ A) - SKDG- (K) 6 -SKTKCVIM is [H] farnesyl on its cysteine C, by farnesyl transferase in the presence of [H] FPP. It is then brought into contact with balls PVT * -streptavidin (AMERSHAM) ®, and is quantified by proximity scintUlation (SPA assay) between tritium and PVT bi
- the farnesyl transferase purified according to the attached protocol is diluted for this assay to a concentration such that a consumption of substrates less than 30% is obtained.
- the final molar concentrations of each substrate are adjusted to their respective Km: 50 nM for the biotinylated K-ras peptide and 120 nM for the FPP, brought under 20 ⁇ l in a final volume of 100 ⁇ l of the reaction mixture based on HEPES 50 buffer.
- the inhibitors to be tested initially dissolved at 1 mM in a suitable solvent (DMF or DMSO) are diluted in the assay buffer and are added in the form of 10 ⁇ l, in tripUcate, to the reaction mixture at a concentration 10 times greater than their final concentration.
- the reaction carried out in OPTIPLATES 96® microtiter plates, is initiated by the enzyme and lasts sixty minutes at 37 ° C. EUe is stopped by adding 150 ⁇ l of mixture of a stop buffer at pH 4 consisting of H 3 PO 0.2 M, MgCl 2 1.5 mM, BSA 0.5% (w / v), sodium azide 0.05 % (w / v) containing 200 ⁇ g of PVT-streptavidin biUes.
- the plates are read in [ 3 H] CPM in a scintUlation counter for TOP COUNT® microplates (PACKARD) where they are transformed into [ 3 H] DPM from '' a range of colored agents reducing scintUlation (“quenching”).
- the inhibition percentages are calculated relative to a control without inhibitor after subtracting all the ceUe values from a blank containing only the substrates and the buffer.
- the IC 50s are calculated or measured from the inhibitions obtained at nine different concentrations with the Enzfitter® or Grafit® ' software.
- the compounds according to the invention tested have IC 50 values between O.lnM and lO ⁇ M.
- EXAMPLE B The activity of the compounds according to the invention can also be evaluated by the capacity of said compounds to inhibit the agar growth of clones derived from human tumor cells.
- cells from the HCT116 human carcinoma shell, supplied by the ATCC are grown in a monolayer in a culture medium, Dubelcco modified Eagle, containing 2 mM of L-glutamine, 200 U / ml of penicillin, 200 ⁇ g / ml of streptomycin supplements with 10% by volume of heat-inactivated fetal calf serum.
- the cells in exponent growth are trypsinized, washed with PBS and diluted to a final concentration of 5000 cells / ml in complete culture medium.
- the inhibitors to be tested, or the control solvent are then added, in a volume of 50 ⁇ l, to 2.5 ml of suspension of ceUules, prepared previously, then 0.4 ml of an agar solution, Noble Difco, maintained at 45 ° C and then mixed.
- the medium thus obtained is immediately thrown into petri dishes, kept for five minutes at 4 ° C. and then incubated at 37 ° C. under an atmosphere of 5% CO 2 .
- the number of cell clones (> 50 cells) is counted after twelve days of incubation at 37 ° C. under an atmosphere of 5% CO 2 .
- Each inhibitor is tested in dupUcate at final agar concentrations of 10, 1, 0.1 0.01 and 0.001 ⁇ g / ml.
- the results are expressed as a percentage of clonogenicity inhibition compared to the untreated controls.
- the IC5 0 inhibitory doses are determined graphically from the semi-logarithmic means of the values obtained for each concentration.
- the products according to the invention inhibit the farnesylation of the Ras protein by 50% at concentrations of between 0.1 nM and 100 ⁇ M.
- capsules containing 50 mg of active product having the following composition are prepared:
- Tablets containing 50 mg of active product having the following composition are prepared according to the usual technique:
- a solution for injection containing 50 mg of active product having the following composition is prepared:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000526514A JP2001527078A (ja) | 1997-12-23 | 1998-12-21 | 新規なファルネシルトランスフェラーゼインヒビター、それらの製造、それらを含有する製薬学的組成物及び医薬品の製造のためのそれらの使用 |
EP98962528A EP1042329A1 (fr) | 1997-12-23 | 1998-12-21 | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
AU17675/99A AU1767599A (en) | 1997-12-23 | 1998-12-21 | Novel farnesyl transferase inhibitors, preparation, pharmaceutical compositions containing them and use for preparing medicines |
CA002315144A CA2315144A1 (fr) | 1997-12-23 | 1998-12-21 | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9716335A FR2772764B1 (fr) | 1997-12-23 | 1997-12-23 | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
FR97/16335 | 1997-12-23 | ||
US7380098P | 1998-02-05 | 1998-02-05 | |
US60/073,800 | 1998-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999033834A1 true WO1999033834A1 (fr) | 1999-07-08 |
Family
ID=26234014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/002804 WO1999033834A1 (fr) | 1997-12-23 | 1998-12-21 | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1042329A1 (fr) |
JP (1) | JP2001527078A (fr) |
AU (1) | AU1767599A (fr) |
CA (1) | CA2315144A1 (fr) |
WO (1) | WO1999033834A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037076A1 (fr) * | 1998-12-21 | 2000-06-29 | Aventis Pharma S.A. | Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine pour le traitement de cancers |
FR2796641A1 (fr) * | 1999-07-22 | 2001-01-26 | Aventis Pharma Sa | Nouveau procede de preparation de composes benzoperhydroisoindole |
EP1656931A1 (fr) * | 2004-11-15 | 2006-05-17 | Exonhit Therapeutics SA | Composées qui son inhibiteurs de protéines prényl transferase pour le traitement de la maladie Parkinson |
EP1732549A2 (fr) * | 2004-03-18 | 2006-12-20 | The Brigham And Women's Hospital, Inc. | Procedes pour le traitement de synucleinopathies |
EP1744751A2 (fr) * | 2004-03-18 | 2007-01-24 | The Brigham And Women's Hospital, Inc. | Traitement des synucleinopathies |
EP1809265A2 (fr) * | 2004-03-18 | 2007-07-25 | The Brigham And Women's Hospital, Inc. | Procedes pour le traitement de synucleinopathies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2736641A1 (fr) * | 1995-07-10 | 1997-01-17 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
-
1998
- 1998-12-21 AU AU17675/99A patent/AU1767599A/en not_active Abandoned
- 1998-12-21 JP JP2000526514A patent/JP2001527078A/ja active Pending
- 1998-12-21 CA CA002315144A patent/CA2315144A1/fr not_active Abandoned
- 1998-12-21 EP EP98962528A patent/EP1042329A1/fr not_active Withdrawn
- 1998-12-21 WO PCT/FR1998/002804 patent/WO1999033834A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2736641A1 (fr) * | 1995-07-10 | 1997-01-17 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037076A1 (fr) * | 1998-12-21 | 2000-06-29 | Aventis Pharma S.A. | Combinaisons des inhibiteurs de farnesyle transferase et irinotecan ou camptothecine pour le traitement de cancers |
FR2796641A1 (fr) * | 1999-07-22 | 2001-01-26 | Aventis Pharma Sa | Nouveau procede de preparation de composes benzoperhydroisoindole |
WO2001007408A2 (fr) * | 1999-07-22 | 2001-02-01 | Aventis Pharma S.A. | Nouveau procede de preparation de composes benzoperhydroisoindole |
WO2001007408A3 (fr) * | 1999-07-22 | 2001-05-17 | Aventis Pharma Sa | Nouveau procede de preparation de composes benzoperhydroisoindole |
EP1732549A2 (fr) * | 2004-03-18 | 2006-12-20 | The Brigham And Women's Hospital, Inc. | Procedes pour le traitement de synucleinopathies |
EP1744751A2 (fr) * | 2004-03-18 | 2007-01-24 | The Brigham And Women's Hospital, Inc. | Traitement des synucleinopathies |
EP1809265A2 (fr) * | 2004-03-18 | 2007-07-25 | The Brigham And Women's Hospital, Inc. | Procedes pour le traitement de synucleinopathies |
EP1809265A4 (fr) * | 2004-03-18 | 2009-06-17 | Brigham & Womens Hospital | Procedes pour le traitement de synucleinopathies |
EP1732549A4 (fr) * | 2004-03-18 | 2009-11-11 | Brigham & Womens Hospital | Procedes pour le traitement de synucleinopathies |
EP1744751A4 (fr) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | Traitement des synucleinopathies |
EP1656931A1 (fr) * | 2004-11-15 | 2006-05-17 | Exonhit Therapeutics SA | Composées qui son inhibiteurs de protéines prényl transferase pour le traitement de la maladie Parkinson |
WO2006051423A1 (fr) * | 2004-11-15 | 2006-05-18 | Exonhit Therapeutics Sa | Composes inhibant la prenylation de proteines, notamment des inhibiteurs de la geranylgeranyltransferase ou de la farnesyltransferase, utilises dans le traitement de la maladie de parkinson |
Also Published As
Publication number | Publication date |
---|---|
CA2315144A1 (fr) | 1999-07-08 |
JP2001527078A (ja) | 2001-12-25 |
EP1042329A1 (fr) | 2000-10-11 |
AU1767599A (en) | 1999-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0711280B1 (fr) | Derives de perhydroisoindole comme antagonistes de la substance p | |
EP0429366B1 (fr) | Nouveaux dérivés de l'isoindolone, leur préparation et les compositions pharmaceutiques qui les contiennent | |
US6013662A (en) | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments | |
EP0635003B1 (fr) | Derives de perhydroisoindole comme antagonistes de la substance p | |
EP0580502B1 (fr) | 3-(hydroxybenzylidényl)-indoline-2-ones, et les compositions pharmaceutiques qui les contiennent | |
FR2676446A1 (fr) | Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent. | |
FR2665159A1 (fr) | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. | |
WO1998022459A1 (fr) | Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments | |
FR2727411A1 (fr) | Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
WO1999033834A1 (fr) | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments | |
EP0625153B1 (fr) | Derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent | |
FR2663331A1 (fr) | Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent. | |
EP0948483B1 (fr) | Inhibiteurs de farnesyle transferase | |
WO2001007408A2 (fr) | Nouveau procede de preparation de composes benzoperhydroisoindole | |
FR2772764A1 (fr) | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments | |
EP0233801B1 (fr) | Nouveaux amides substitués, leur préparation et les compositions pharmaceutiques qui les contiennent | |
EP0373061A1 (fr) | Nouveaux dérivés de l'indole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
FR2796640A1 (fr) | Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments | |
EP0196955B1 (fr) | Nouveaux dérivés de la pyrrolo[1,2-a]azépinone, leur préparation et les compositions pharmaceutiques qui les contiennent | |
EP0027085B1 (fr) | Nouveaux dérivés de la thiazolo (3,2-c) benzoxazine-1,3, leur préparation et les médicaments qui les contiennent | |
WO2001009124A1 (fr) | Derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapique | |
FR2796948A1 (fr) | Nouveaux derives 8-carbonyl chromannes, leur preparation et leur utilisation en therapeutique | |
FR2695389A1 (fr) | Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent. | |
WO1999041242A1 (fr) | Derives de naphtyl disubstitues, leur preparation, les compositions pharmaceutiques qui les contiennent | |
FR2553415A2 (fr) | Derives de l'indole, leur preparation et leur application en therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2315144 Country of ref document: CA Ref country code: CA Ref document number: 2315144 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998962528 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09598439 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998962528 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998962528 Country of ref document: EP |